BioSpace News Archive

FreezeM, an Agri-tech pioneering biotechnology company that offers Breeding-as-a-Service for Black Soldier Fly protein factories, announced the closure of $14.2 million in Series A funding.

Halia Therapeutics announced the initiation of its Phase II randomized, single-dose, placebo-controlled, double-blind, parallel-group clinical study to evaluate the efficacy of HT-6184, a selective and orally bioavailable first-in-class inhibitor of the NEK7/NLRP3 inflammasome, a main driver of inflammatory diseases.

IceCure Medical Ltd., developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced Eisuke Fukuma, MD, PhD, who has performed over 600 breast cryoablation procedures with ProSense®, will host events that feature ProSense® at two upcoming medical conferences in Japan.